



Listing of Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (Currently Amended) A method according to claim 5, wherein the disease is of treating or preventing Alzheimer's disease, in a subject in need of such treatment comprising administering a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof:




wherein Ar is




R_{10} is H or OH;

X is O or an electron pair;

W is




Q is




Z is H or Z and Q taken together are ~~$(CH_2)_3$ or $(CH_2)_4$~~


U is



~~R_3 is C_{1-11} -alkyl or~~




~~wherein R_{20} is H or C_{1-10} -alkyl; and Ac is formyl or~~



~~wherein R_{21} is C_{1-10} -alkyl;~~

L is



~~p is 0, 1 or 2; and~~

~~q is 0, 1, or 2;~~


~~an epimer or racemate thereof.~~

2. (Original) A method of treating Alzheimer's disease in a subject in need of such treatment comprising administering to the subject a compound disclosed in claim 1, or a pharmaceutically acceptable salt thereof.


3. (Original) A method of treating Alzheimer's disease by modulating the activity of beta amyloid converting enzyme, comprising administering to a subject in need of such treatment a compound disclosed in claim 1, or a pharmaceutically acceptable salt thereof.

4. (Original) The method according to claim 1, further comprising the administration of a P-gp inhibitor, or a pharmaceutically acceptable salt thereof.

5. (Original) A method of treating a subject who has, or in preventing a subject from getting, a disease or condition selected from the group consisting of Alzheimer's disease, for helping prevent or delay the onset of Alzheimer's disease, for treating subjects with mild cognitive impairment (MCI) and preventing or delaying the onset of Alzheimer's disease in those who would progress from MCI to AD, for treating Down's syndrome, for treating humans who have Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-Type, for treating cerebral amyloid angiopathy and preventing its potential consequences, i.e. single and recurrent lobar hemorrhages, for treating other degenerative dementias, including dementias of mixed vascular and degenerative origin, dementia associated with Parkinson's disease, frontotemporal dementias with parkinsonism (FTDP), dementia associated with progressive supranuclear palsy, dementia associated with cortical basal degeneration, or diffuse Lewy body type of Alzheimer's disease and who is in need of such treatment which includes administration of a therapeutically effective amount of a compound of formula (I)




wherein Ar is




R₁₀ is H or OH;


X is O or an electron pair;

W is




Q is






Z is H or Z and Q taken together are $-(CH_2)_3-$ or $-(CH_2)_4-$


U is



R_3 is C_{1-11} -alkyl or




wherein R_{20} is H or C_{1-10} -alkyl; and Ac is formyl or



wherein R_{21} is C_{1-10} -alkyl;

L is


CNCCOCCOC

p is 0, 1 or 2; and

q is 0, 1, or 2;

an epimer or racemate thereof.


6. (Currently Amended) The method according to claim 5, ~~any of claims 1-5~~ wherein Ar is



7. (Currently Amended) The method according to claim 5, ~~any of claims 1-5~~ wherein W is selected from the group consisting of -SO₂- and -CO-.

8. (Currently Amended) The method according ~~according to claim 5, any of~~ ~~claims 1-5~~ wherein W is -CO-.

9. (Currently Amended) The method according to claim 5, ~~any of claims 1-5~~ wherein Q is selected from the group consisting of




10. (Currently Amended) The method according to claim 5, ~~any of claims 1-5~~ wherein Q is




11. (Currently Amended) The method according to claim 5, ~~any of claims 1-5~~ wherein Q is




12. (Currently Amended) The method according to claim 5, ~~any of claims 1-5~~ wherein U is selected from the group consisting of




13. (Currently Amended) The method according to claim 5, ~~any of claims 1-5~~ wherein U is



14. (Currently Amended) The method according to claim 5, ~~any of claims 1-5~~ wherein -O-L is




15. (Currently Amended) The method according to claim 5, ~~any of claims 1-5~~ wherein -O-L is



































16. (Currently Amended) The method according to claim 5, ~~any of claims 1-5~~ wherein R_2 is selected from the group consisting of NH-tBu or NH-Ph .

17. (Currently Amended) A method according to claim 5, ~~of treating or preventing Alzheimer's disease in a subject in need of such treatment~~ comprising


administering a therapeutically effective amount of a compound selected from the group consisting of:




Compound	Ar-W-	Q	U	L
A				
B				
C				
D				
E				
F				
G				
H				
I				

J		 CONH ₂	 NH ₂ (S)	 NH tBu
K		 CONH ₂	 N ₃ (S)	 NH tBu
L		 CONH ₂	 NH ₂ (S)	 NH tBu
M		 CONH ₂	 N ₃ (S)	 NH tBu
N		 CONH ₂	 NH ₂ (S)	 NH tBu
O		 CONH ₂	 N ₃ (S)	 NH tBu
P		 CONH ₂	 NHAc (S)	 NH tBu
Q		 CONH ₂	 NH ₂ (R)	 NH tBu






R				
S				
T				




wherein * denotes all the possible stereoisomers at the particular carbon, and mixtures thereof;



or a mixture thereof;







or pharmaceutically acceptable salts thereof.




18. (Canceled)

19. (Original) A method for inhibiting beta-secretase activity, comprising contacting an effective amount for inhibition of a compound of formula (I)




wherein Ar is










 or
 

W is




19




Z is H or Z and Q taken together are $-(CH_2)_3-$ or $-(CH_2)_4-$


U is



R_3 is C_{1-11} -alkyl or




wherein R_{20} is H or C_{1-10} -alkyl; and Ac is formyl or




wherein R_{21} is C_{1-10} -alkyl;





L is



or



R_2 is




m is 0, 1 or 2;

p is 0, 1 or 2; and




q is 0, 1, or 2;
an epimer or racemate thereof.

20. (Canceled)


21. (Original) A method for inhibiting production of amyloid beta peptide (A beta) in a cell, comprising administering to said cell an effective inhibitory amount of a compound of formula (I) or pharmaceutically acceptable salt thereof:



wherein Ar is




* indicates a mixture of isomers at this carbon










R_{10} is H or OH;

X is O or an electron pair;

W is




Q is




Z is H or Z and Q taken together are $-(CH_2)_3-$ or $-(CH_2)_4-$


U is



R_3 is C_{1-11} -alkyl or




wherein R_{20} is H or C_{1-10} -alkyl; and Ac is formyl or




wherein R_{21} is C_{1-10} -alkyl;





L is



or



R_2 is



m is 0, 1 or 2;

p is 0, 1 or 2; and

q is 0, 1, or 2;
an epimer or racemate thereof.

22. (Original) The method of claim 21, wherein the cell is an animal cell.
23. (Original) The method of claim 22, wherein the animal cell is a mammalian cell.
24. (Original) The method of claim 23, wherein the mammalian cell is human.
25. (Canceled)
26. (Canceled)
27. (Canceled)
28. (Canceled)
29. (Canceled)
30. (Currently Amended) A method of treatment according to claim 5, ~~any of claims 1-6~~, further comprising administration of one or more therapeutic agents selected from the group consisting of an antioxidant, an anti-inflammatory, a gamma secretase inhibitor, a neurotrophic agent, an acetyl cholinesterase inhibitor, a statin, P-gp inhibitors, an A beta peptide, and an anti-A beta peptide.